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Abstract
Purinergic signaling regulates several renal physiological and pathophysiological 
processes. Extracellular vesicles (EVs) are nanoparticles released by most cell types, 
which, in non- renal tissues, modulate purinergic signaling. The aim of this study 
was to investigate the effect of EVs from renal proximal tubule (HK2) and collect-
ing duct cells (HCD) on intra- and intersegment modulation of extracellular ATP 
levels, the underlying molecular mechanisms, and the impact on the expression of the 
alpha subunit of the epithelial sodium channel (αENaC). HK2 cells were exposed to 
HK2 EVs, while HCD cells were exposed to HK2 and HCD EVs. Extracellular ATP 
levels and αENaC expression were measured by chemiluminescence and  qRT- PCR, 
respectively. ATPases in EV populations were identified by mass spectrometry. The 
effect of aldosterone was assessed using EVs from aldosterone- treated cells and uri-
nary EVs (uEVs) from primary aldosteronism (PA) patients. HK2 EVs downregu-
lated ectonucleoside- triphosphate- diphosphohydrolase- 1 (ENTPD1) expression, 
increased extracellular ATP and downregulated αENaC expression in HCD cells. 
ENTPD1 downregulation could be attributed to increased miR- 205- 3p and miR- 505 
levels. Conversely, HCD EVs decreased extracellular ATP levels and upregulated 
αENaC expression in HCD cells, probably due to enrichment of 14- 3- 3 isoforms with 
ATPase activity. Pretreatment of donor cells with aldosterone or exposure to uEVs 
from PA patients enhanced the effects on extracellular ATP and αENaC expression. 
We demonstrated inter- and intrasegment modulation of renal purinergic signaling by 
EVs. Our findings postulate EVs as carriers of information along the renal tubules, 
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1 |  INTRODUCTION
Purinergic signaling constitutes a key regulatory mecha-
nism in several renal physiological and pathophysiological 
processes.1 For instance, extracellular nucleotides have been 
described to modulate reabsorption of ions, water, and other 
solutes (eg, urea) from the pro- urine.1 Hereby, the epithelial 
sodium channel (ENaC) constitutes a major purinergic tar-
get.2 Purinergic signaling results from the binding of extracel-
lular ATP and its hydrolysis products to purinergic receptors 
of the P1 (ie, adenosine receptors) and P2 (ie, nucleotide 
receptors) families.3 In the kidney, purinergic receptors are 
expressed throughout the different segments of the nephron 
as well as in the glomeruli, endothelial, and smooth muscle 
cells from the afferent and efferent arterioles.3 Extracellular 
ATP levels result from the balance between ATP release by 
channels such as pannexin 1 (PANX1)4 and connexin 305 and 
ATP hydrolysis by ecto- ATPases.6 Among the latter, mem-
bers like the ectonucleotidase 2 (ENTPD2, ectonucleoside 
triphosphate diphosphohydrolase 2, NTPDase 2) catalyze 
the hydrolysis of ATP to ADP, which also represents a P2 ag-
onist. On the contrary, the ectonucleotidase 1 (ENTPD1, ec-
tonucleoside triphosphate diphosphohydrolase 1, NTPDase 
1, CD39) catalyzes the hydrolysis of ATP to AMP and results 
in an attenuation of P2- mediated signaling.6 Although the 
role of ENTPD1 in the pathogenesis of diseases such as pul-
monary hypertension7 and Crohn's disease8 is well acknowl-
edged, the regulatory mechanisms of ecto- ATPases, as well 
as of ATP secreting channels in the kidney have been less 
investigated.
Extracellular vesicles (EVs) are a group of membrane- 
enclosed nanosized particles released by several types of 
cells mainly consisting of exosomes and microvesicles.9 
EVs carry proteins, RNA (eg, microRNAs, mRNAs), signal-
ing lipids,10 metabolites,11 and carbohydrates12 within their 
cargo, which ultimately determine the biological effect of a 
given set of EVs. In the kidney, research has focused mainly 
on urinary EVs (uEVs), released by the epithelial cells from 
the renal tubules and the urinary tract, and their potential 
as a source of biomarkers for renal disorders.13,14 However, 
more interest has been placed recently in the role of EVs in 
the regulation of renal physiological and pathophysiologi-
cal processes (overview recently reviewed in Rigalli et al15). 
Noteworthy, the intrinsic structure of EVs, where the cargo 
is protected from proteases and RNAses by a lipid bilayer, 
may provide an efficient way for the intercellular shuttle of 
molecules and signals between different segments of the 
nephron in a chemically aggressive environment such as 
the pro- urine.16 This way, cells located in distal segments 
of the nephron may be able to receive signals from cells in 
the more proximal segments. For instance, Jella et al17 re-
ported the inhibition of ENaC in collecting duct cells ex-
posed to EVs derived from proximal tubule cells. In another 
study, the transfer of functional aquaporin 2 (AQP2) by EVs 
within different collecting duct cells has been described.18 
Interestingly, AQP2 activity in the target cells was higher 
when donor cells (ie, EV- releasing cells) had been previ-
ously exposed to the vasopressin analogue desmopressin.18 
Moreover, proteomics and next- generation sequencing stud-
ies performed on uEVs confirmed the presence of more than 
1,000 proteins and 500 miRNA and pre- miRNA molecules 
with different biological activities.19,20 Similarly, a proteom-
ics analysis of EVs isolated from cortical collecting duct 
cells identified the presence of more than 100 proteins.21 
This extremely diverse cargo confers EVs an immense po-
tential to mediate other, yet unknown, renal physiological 
processes, in particular those involving the remote exchange 
of information between cells.
Modulation of purinergic signaling by EVs has already 
been described, although not yet in the kidney. For instance, 
EVs isolated from pleural fluid from mesothelioma patients 
exhibited ENTPD1 activity mediating the hydrolysis of ex-
tracellular ATP to AMP, which was further hydrolyzed to 
adenosine by CD73, also present in the vesicles.22 Finally, 
adenosine binding to A2A receptors suppressed T- cell acti-
vation and thus the antitumoral response.22 In another study, 
exosomes released by head and neck squamous cell carci-
noma cells upregulated ENTPD1 expression in T- regulatory 
lymphocytes, also showing the potential of EVs to regulate 
purinergic signaling.23 Considering this, we hypothesize that 
EVs secreted by renal tubular epithelial cells modulate extra-
cellular ATP levels and, therefore, purinergic signaling.
The aim of this study was to investigate the effect of EVs 
from renal proximal tubule and collecting duct cells on ex-
tracellular ATP levels, the underlying molecular mechanisms 
and the downstream impact on the expression of SCNN1A 
(ie, subunit alpha of the epithelial sodium channel, αENaC), 
a well- known purinergic target.24,25
whereby processes affecting EV release and/or cargo may impact on purinergically 
regulated processes.
K E Y W O R D S
aldosterone, epithelial sodium channel, exosomes, extracellular vesicles, purinergic signaling
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2 |  MATERIALS AND METHODS
2.1 | Materials
Dynasore, POM1, and suramin were from Santa Cruz 
Biotechnology (Dallas, TX, USA). Apyrase and γ- S- ATP 
were from Sigma- Aldrich (St. Louis, MO, USA). All rea-
gents were of analytical grade quality or higher.
2.2 | Cell culture
Human proximal tubule epithelial cells (HK2, 
ATCC®CRL- 2190™, passage number 15- 30) kindly do-
nated by Dr Rody San Martín (UACh; Valdivia, Chile) 
were cultured under standard conditions. Cells were cul-
tured in medium consisting of DMEM- F12 low glucose 
(5  mM) supplemented with 10% (v/v) fetal bovine serum 
(FBS), penicillin/streptomycin, non- essential amino acids 
and HEPES (20  mM). Human collecting duct cells (HCD, 
passage number 20- 30), kindly donated by Dr Pierre Ronco 
(Hôpital Tenon, Paris, France), were cultured in DMEM- F12 
supplemented with FBS 2% (v/v), penicillin/streptomycin, 
transferrin (5 μg mL−1), sodium selenite (50 nM), glutamine 
(2 mM), dexamethasone (50 nM), insulin (5 μg mL−1), and 
HEPES (20 mM).26 Both cell types were cultured at 37°C in 
an incubator with 5% (v/v) CO2 and humidified atmosphere, 
trypsinized and passaged when they reached 80% confluence.
2.3 | Isolation of EVs
HK2 and HCD EVs for cell treatments were isolated using 
a differential ultracentrifugation protocol.27,28 In brief, HK2 
and HCD cells were seeded in 8 T- 175 flasks (2x106 cells 
per flask) and cultured for 24  hours up to 30%- 40% con-
fluence as described by Sinha et al29 Afterward, cells were 
rinsed with PBS and 20  mL per flask of EV- free medium 
were added. FBS- free or low FBS (1% (v/v), EV- depleted) 
medium was used for HK2 cells or HCD cells, respec-
tively. FBS was depleted of EVs using ultracentrifugation 
at 100  000  g for 18  hours as previously described.30 Cells 
were incubated for 24 hours. Subsequently, the culture me-
dium was collected and centrifuged at 300 g for 15 minutes 
to remove the remaining cells. The supernatant was centri-
fuged at 2000  g for 30  minutes and again at 12  000  g for 
45 minutes in order to remove dead cells, apoptotic bodies, 
and cell debris, respectively. The resulting supernatant was 
filtered using a Ministart 0.22 μm syringe filter (Sartorius, 
Göttingen, Germany) and ultracentrifuged at 120 000 g for 
70 minutes (Sorvall WX + Ultra Series; AH629- 36 swinging 
bucket rotor). The resulting pellet was resuspended in PBS, 
washed, and ultracentrifuged at 100  000  g for 70  minutes. 
The final pellet was resuspended in 100 μL of filtered PBS. 
Unless otherwise stated, EV suspensions for cell treatments 
were obtained by pooling six different preparations ob-
tained as described above. Suspensions were characterized 
according to the guidelines of the International Society for 
Extracellular Vesicles31 by nanoparticle tracking analysis, 
transmission electron microscopy, and western blot analysis. 
Aliquots were stored at −80°C until further analysis or use 
for cell treatments.
2.4 | Nanoparticle tracking analysis
To quantify vesicle size and concentration of the EV suspen-
sions, Nanoparticle Tracking Analysis (NTA) was performed 
using a NanoSight NS300 and NanoSight NTA 3.2 software 
(Malvern Instruments Ltd, Malvern, UK). Samples were op-
timized for analysis by diluting them in filtered PBS within 
a range of concentrations to obtain around 20- 100 particles 
per field. Once the appropriate dilution was obtained, sam-
ples were introduced in a low- volume flow cell (Malvern 
Instruments Ltd, Malvern, UK) using an automatic syringe 
pump. Camera level and detection threshold were optimized 
to obtain an image with enough contrast to identify individual 
particles and minimum background noise during recordings 
(camera level = 13; detection threshold = 3; flow speed = 50 
arbitrary units). Particles were tracked by passing a laser 
beam through the liquid sample, and the scattered light was 
detected and captured in short videos by a sCMOS camera (3 
videos of 30 seconds each). The Brownian motion of parti-
cles was determined on a frame- by- frame basis and the dis-
tance moved by particles was used to determine EVs size and 
concentration using the Stokes- Einstein equation.
2.5 | Transmission electron microscopy
Transmission electron microscopy (TEM) was performed to 
verify the shape and size of EVs isolated using the protocol 
described above. Briefly, 15  μL of the EV suspension were 
absorbed onto carbon- coated copper grids (200 mesh) for 
10 minutes. Samples were negatively stained with 2% (w/v) 
uranyl acetate solution for 1 minute. Grids were visualized 
at 87 000× in a Phillips Tecnai transmission electron micro-
scope at 80 kV, and images were acquired using a SIS CCD 
Camera Megaview G2.32 To determine EV size, TEM micro-
photographs were analyzed using ImageJ (NIH, USA).
2.6 | Western blot analysis
CD63 as an EV marker, ENTPD1 and PANX1 protein ex-
pression were determined using western blot analysis. For 
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this purpose, EVs (for CD63) or cell pellets (for ENTPD1 
and PANX1) were resuspended in RIPA buffer (Thermo 
Fisher Scientific Inc, IL, USA) to extract total proteins and 
protein concentration was determined using the bicinchoninic 
acid (BCA) method.33 Protein lysates were separated by 
polyacrylamide gel electrophoresis and transferred to ni-
trocellulose membranes (Bio- Rad, CA, USA). Membranes 
were incubated with primary antibodies: mouse monoclonal 
anti- CD63 (1:200, sc5275, Santa Cruz Biotechnology, TX, 
USA), rabbit monoclonal anti- CD39 (ie, ENTPD1) (1:1000, 
ab108248, Abcam, Cambridge, UK), rabbit polyclonal anti- 
PANX1 (1:1000, ab139715, Abcam, Cambridge, UK), or 
mouse- monoclonal anti- beta actin (1:10 000, A5441, Sigma- 
Aldrich, St. Louis, MO, USA) overnight at 4°C. Next, they 
were washed three times with 0.3% (v/v) TBS- Tween and 
incubated with the correspondent secondary HRP- linked an-
tibody: rabbit anti- mouse (1:10 000, Ab6728, Abcam, MS, 
USA) or goat anti- rabbit (1:10 000, #7074, Cell Signaling, 
MA, USA) for 1  hour at room temperature, washed three 
times with TBS- T. Finally, proteins were detected with en-
hanced chemiluminescence using a ChemiDoc Imaging 
System (Bio- Rad, CA, USA).
2.7 | Cell treatments
To investigate the effect of EVs on extracellular ATP and 
purinergic signaling, HK2 cells were exposed to HK2 EVs 
(ie, signaling within the proximal tubule), while HCD cells 
were exposed to HK2 (ie, signaling from the proximal tubule 
to the collecting duct) and HCD EVs (ie, signaling within 
the collecting duct). As a control, the effect of HCD EVs on 
extracellular ATP levels in HK2 cells was investigated. HK2 
and HCD cells were seeded in 12- well plates (5 × 104 cells/
well, for extracellular ATP measurements) or 6- well plates 
(1.125 × 105 cells/well, for intracellular cAMP and expres-
sion analysis) and cultured for 24 hours in complete medium 
under standard conditions. Then, cells were rinsed with PBS, 
and starving medium (FBS- free or supplemented with 1% 
(v/v) of EV- depleted FBS, for HK2 and HCD cells, respec-
tively) was added for 24 hours. Next, medium was replaced 
with fresh starving medium supplemented with HK2 or HCD 
EVs (7  ×  107 particles/mL of culture medium)17 and cells 
were incubated for 15 minutes (to study short- term effects) 
and 6  hours (to study long- term effects). After incubation, 
aliquots of culture medium were collected for extracellular 
ATP quantification, and cell pellets were obtained for expres-
sion analysis. The expression of αENaC, a well- known target 
of purinergic signaling,24 was investigated. Dependence of 
extracellular ATP changes on the EV uptake by the target 
cells was studied by co- incubation with dynasore (80 μM), 
used as an uptake inhibitor.34 The participation of ENTPD1 
in mediating the changes in extracellular ATP was assessed 
using the inhibitor POM1 (25  μM).35 All ENTPD1 inhibi-
tion experiments included a 30- minutes preincubation with 
the inhibitor. The association between the regulation of 
extracellular ATP and αENaC expression by EVs was ad-
dressed by co- incubation of cells with EV suspensions under 
depletion of extracellular ATP with apyrase (24 U mL−1).36 
Furthermore, the relevance of variable extracellular ATP was 
also determined by incubation with the non- hydrolyzable 
ATP analogue ATP- γ- S (5 and 50 μM).37 The participation 
of P2Y receptors in αENaC regulation by EVs was assessed 
using suramin (50 μM).38
2.8 | Confirmation of EV uptake by 
target cells
HK2 and HCD- derived EV pellets, isolated as previously 
described, were resuspended in filtered PBS and stained 
for 5  minutes with PKH67 green fluorescent cell linker kit 
(Sigma- Aldrich, MO, USA) and diluent C. The reaction was 
stopped using PBS- BSA 5% (w/v) for 1 minute. The mix was 
ultracentrifuged at 100 000 g for 70 minutes, and the pellet 
washed with PBS and ultracentrifuged twice at 100 000 g for 
70  minutes. The final pellet was resuspended in 100  μL of 
PBS. Stained EVs were incubated on target cells (HK2 and 
HCD) grown on coverslips for 12  hours. After incubation, 
cells were fixed using 4% (w/v) paraformaldehyde for 10 min-
utes at room temperature. As a negative control, cells were 
exposed to free dye incubated without EVs (PKH67 and 5% 
(w/v) BSA). Cell nuclei were stained with DAPI for 1 minute, 
rinsed with PBS, mounted in a glass slide using mounting me-
dium and visualized in an epifluorescence microscope.
2.9 | Quantification of extracellular ATP
To assess the effect of EVs on extracellular ATP levels, 
cells were treated as described in Section 2.7. Extracellular 
ATP was measured using the ATP Lite kit (Perkin- Elmer, 
Waltham, MA, USA). After treatment, aliquots of culture 
medium were diluted in the lysis buffer provided with the 
kit and used for ATP determinations by chemiluminescence 
following the manufacturer's instructions.
To confirm the participation of EVs in the regulation 
of extracellular ATP levels, EV suspensions from HK2 and 
HCD cells generated as described in Section  2.3 were de-
pleted from EVs using the Exosome human CD63 Isolation/
detection reagent (Thermo Fisher Scientific Inc, IL, USA). 
Next, the EV- depleted suspension was added to HCD cells 
in a volume equivalent to the volume of original suspen-
sion leading to a concentration of 7x107 EVs/mL of culture 
medium (ie, 0.02  μL suspension/mL of culture medium). 
Extracellular ATP levels were measured after 6  hours of 
   | 5 of 18BARROS LAMUS et AL.
incubation using the ATP Lite kit (Perkin- Elmer, Waltham, 
MA, USA). EV- depletion was confirmed by western blot for 
CD63 (see Section 2.6.).
2.10 | Gene expression analysis
Total RNA was isolated from target cells treated with EVs 
using the RNeasy Mini Kit (Qiagen, Hilden, Germany). 
Reverse transcription and real- time quantitative PCR were 
performed as previously described.39 RPS11 was used as 
a reference gene. Primer sequences were: ENTPD1 (F): 
5′TCAAATGGTGAAGGTGGGCA3′; ENTPD1 (R): 5′GG 
AGAACCAGAACCACAGCA3′; ENTPD2 (F): 5′CTCCT 
ACTGCTGTGCGTCC3′; ENTPD2 (R): 5′TGTCGTT 
CTCCTTGTCTGCC3′; PANX1 (F): 5′GTGGCTGCA 
TAAGTTTTTCCCC3′; PANX1 (R):5′GCAGCCTTAAT 
TGCACGGTT3′; P2RY1 (F): 5′CTCTGCCAGCCCTGA 
TCTTC3′; P2RY1 (R): 5′GACCCCGGTACCTGAGTAGA3′; 
P2RY2 (F): 5′ATCAATGGCACCTGGGATGG3′; P2RY2 
(R): 5′ACGCATTCCAGGTCTTGAGG3′; P2RY11 (F): 
5′CACTCAGCTTCTCCCACCTG3′; P2RY11 (R): 5′TG 
TCCCCAGACACTTGATGC3′; RPS11 (F): 5′AGAG 
GACCATTGTCATCCGC3′; RPS11 (R): 5′AGACATG 
TTCTTGTGGCGCT3′; SCNN1A (F): 5′TCCTGCAAC 
CAGGCGAATTACTCT3′; SCNN1A (R): 5′AGGGACA 
GACCGTTGTTGATTCCA3′.
Potential miRNAs regulating ENTPD1 expression 
were identified by in silico analysis using TargetScan,40 
miRDB,41 and microrna.org42 databases and literature search 
for presence of the miRNA in the kidney, proximal tubule, 
HK2 cells and/or human urine. To experimentally address 
the involvement of miRNAs, small RNAs were isolated 
using the Nucleospin miRNA kit (Macherey- Nagel, Düren, 
Germany). cDNA was synthesized using the miScript II RT 
Kit with the HiSpec buffer (Qiagen, Hilden, Germany) fol-
lowing manufacturer's instructions. qPCR reactions were 
performed as described.35 Forward primer sequences were: 
miR- 21 (F): 5′GCGCTGTAGCTTATCAGACTG3′; miR- 
30a- 5p (F): 5′GCTGCTGTAAACATCCTCG3′; miR- 30b- 
5p (F): 5′GCCGACTGTAAACATCCTACA3′; miR- 125b 
(F): 5′GCTACTCCCTGAGACCCTAAC3′; miR205- 3p 
(F): 5′GCTCAGATTTCAGTGGAGTG3′; miR- 205- 5p: 
5′CTTAATCCTTCATTCCACCG3′; miR- 301a- 5p (F): 
5′GTGCCGCTCTGACTTTATTG3′; miR- 505- 3p (F): 5′GA 
C TCCGTCAACACTTGCT3′; miR- 599 (F): 5′GCTGCG 
TTGTGTCAGTTTAT3′. U6 snRNA expression was quan-
tified with the miScript primer assay (Qiagen, Hilden, 
Germany) and used as the reference for miRNA quantifica-
tion. A universal reverse primer provided with the miScript 
PCR Starter kit (Qiagen, Hilden, Germany) was used for all 
miRNAs and U6 snRNA. In all cases, RNA expression was 
analyzed by the 2- ΔΔCt method.43 miRNA expression was 
plotted as fold- change respect to the control (no EV addition).
2.11 | Determination of intrinsic ATPase 
activity of EV suspensions
Intrinsic ATPase activity of EV suspensions was measured 
in a reaction medium consisting of PBS supplemented with 
ATP (0.1 μM) and the necessary volume of EV suspensions 
(isolated as described in 2.3) in order to achieve final con-
centrations of 5 × 104, 1 × 105 and 2 × 105 EVs per μL−1 of 
the reaction medium. Samples of reaction medium were col-
lected at 6 hours of incubation, and ATP quantification was 
performed as described in 2.9.
2.12 | Proteomics analysis of EV suspensions
Extracts of EVs from HK2 and HCD cells were precipi-
tated with acetone to concentrate the samples. Equal protein 
amounts of all samples were processed simultaneously using 
filter- aided sample preparation (FASP).44 In brief, the sam-
ples were mixed with 200 µL 8 M urea (in 0.1 M HEPES pH 
8.50) in the presence of 0.01 M DTT and loaded onto centrifu-
gal filters (Microcon #MRCF0R030; Merck; Darmstadt, HE, 
Germany) and centrifuged for 15 minutes at 14 000 g. The 
filters were washed once with 8 M urea (in 0.1 M HEPES pH 
8.50) and incubated for 20 minutes in the dark with 100 µL of 
Tris/HCl (0.1 M, pH 8.50) supplemented with iodoacetamide 
(50 mM) and urea (8 M). Following, the filters were centri-
fuged and washed three times with 8  M urea (in 100  mM 
HEPES pH 8.50), followed by three washes with 50  mM 
ammonium bicarbonate. Overnight digestion was performed 
in a wet chamber at 37°C with a 1/100 trypsin:protein ratio. 
After overnight digestion, samples were acidified with trif-
luoroacetic acid (TFA) and desalted using Stage tips.45
The digested peptides were injected into an Easy- 
nLC1000 (Thermo Fisher Scientific Inc, IL, USA) con-
nected online to an LTQ- Orbitrap- Fusion mass spectrometer 
(Thermo Fisher Scientific Inc, IL, USA) with a develop-
ing gradient from 7% to 30% (v/v) buffer B (80% acetoni-
trile, 0.1% (w/v) formic acid in water ) for 214 min prior 
to washes at 60% then 95% (v/v) buffer B, for a total data 
collection time of 240  minutes. Raw files were searched 
against the curated UniProt human proteome database (re-
leased June 2017) with MaxQuant versions 1.6.0.146 and its 
integrated search engine Andromeda with default settings. 
In addition, match between runs, label- free quantification 
(LFQ) and iBAQ were enabled. Prior to downstream anal-
ysis, proteins flagged as reverse or contaminant hits were 
filtered out. Proteins were analyzed using the LFQ values 
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obtained from MaxQuant using the Perseus software (ver-
sion 1.6.5.0).47
2.13 | Effect of EVs on intracellular cAMP
Intracellular cAMP was studied in cells exposed to EVs for 
6  hours as described in Section  2.7. After treatment, cell 
lysates were obtained, and intracellular cAMP was meas-
ured using the Cyclic AMP Select ELISA Kit (Cayman 
Chemical, Ann Arbor, MI, USA) following the manufactur-
er's instructions.
2.14 | Effect of aldosterone on EV 
release and extracellular ATP
HCD cells were cultured as previously described (Section 2.2) 
in complete medium for 24 hours followed by 24 hours of 
incubation in starving medium (ie, with 1% (v/v) of EV- 
free and charcoal- stripped FBS).48 Subsequently, cells were 
stimulated with aldosterone (100  nM) for 24 hours.49,50 
Afterward, the culture medium was collected and EVs were 
isolated. The number of EVs under the different experimen-
tal conditions was assessed by nanoparticle tracking analysis, 
as described in Section 2.4. The effect of EVs from control 
and aldosterone- conditioned cells on extracellular ATP in 
HCD cells was studied by exposing the target cells to the 
same volume of EV suspension (0.02 μL EVs per μL culture 
medium). Extracellular ATP was determined as described 
(Section 2.9.).
2.15 | Effect of uEVs from patients with 
primary aldosteronism on extracellular 
ATP and αΕNaC expression in HCD cells
To study whether uEVs from patients with increased aldos-
terone production and mineralocorticoid activation exert a 
differential effect on extracellular ATP and αENaC expres-
sion, uEVs were isolated from urine samples of patients di-
agnosed with primary aldosteronism (PA). The diagnosis 
of PA was performed according to the endocrine society 
guidelines51 with serum aldosterone to plasma renin activ-
ity ratio (ARR) > 25 and suppressed plasma renin activity 
(<1  ng  mL−1  h−1), after which primary aldosteronism pa-
tients (n = 12) and healthy controls (n = 14) were selected. 
Subjects with underlying comorbidities, or using glucocorti-
coids, contraceptives or drugs that interfere with the renin- 
angiotensin aldosterone system (eg, spironolactone) were 
excluded. Baseline characteristics of both groups of subjects 
are detailed in Supporting Information 1. Informed consent 
was obtained from all participants according to the guidelines 
of the Declaration of Helsinki and Ethics Committee of the 
Faculty of Medicine, Pontificia Universidad Católica de 
Chile (CEC- MedUC #180309002).
Second- morning urine samples (15  mL), collected be-
tween 8:00 and 10:00 AM and mixed with 1  mL of 1X 
Complete Protease Inhibitor Cocktail (Roche, Mannheim, 
Germany), were used to isolate uEVs through a differential 
ultracentrifugation protocol previously described.52 In brief, 
12 mL of urine were centrifuged at 17 000 g, 4°C for 15 min-
utes. The resulting supernatant (SN1) was stored at room 
temperature, and the pellet was resuspended in 50 μL of DTT 
(3.2 M) and 200 μL of isolation solution (10 mM triethanol-
amine and 250  mM sucrose). Afterward, the mix was vor-
texed and centrifuged at 17 000 g, 4°C for 15 minutes. The 
resulting supernatant was mixed with SN1 and centrifuged at 
200 000 g, 20°C for 90 minutes. The final supernatant was 
discarded, and the pellet was resuspended in 100 μL of PBS 
and stored at −80°C until further analysis.
The uEV suspensions from healthy controls and PA pa-
tients were generated by pooling similar volumes from the 
different uEVs preparations, and protein concentration from 
each suspension was determined using the BCA method. 
Afterwards, HCD cells were cultured as described in 2.7, 
and exposed to 10 μg mL−1 of uEV suspensions from healthy 
controls or PA patients for 6 hours. After the treatment, extra-
cellular ATP levels were determined as in 2.9 and SCNN1A 
expression as in 2.10.
2.16 | Statistical analysis
All data are expressed as mean ± SEM. Statistical differ-
ences between groups were assessed with the Student's 
t- test or one- way ANOVA for two or more than two ex-
perimental groups, respectively. Analyses were performed 
with GraphPad Prism 7.0e (GraphPad Software, San Diego, 
CA, USA).
3 |  RESULTS
3.1 | Characterization of EV fractions
Size distribution analysis showed a peak at 84 and 98 nm, 
with a mean size of 86.7 ± 1.9 and 90.0 ± 0.6 nm for HK2 
and HCD EVs, respectively (Figure  1A,B). All particles 
bigger than 0.22  μM were filtered out during the isolation 
process. EV concentration in prepared EV suspensions was 
3.8  ×  108  ±  2.69  ×  107 particles mL−1 for HK2 EVs and 
3.41 × 108 ± 5.84 × 107 particles mL−1 for HCD EVs. Western 
blot analysis confirmed the presence of the EV marker CD63 
in both HK2 and HCD EVs (Figure 1C). Transmission elec-
tron micrographs for both HK2 and HCD EVs showed the 
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characteristic cup- shaped morphology and a size range be-
tween 50 and 150 nm (Figure 1D,E). Fluorescence micros-
copy of target cells incubated with PKH67- labeled EVs 
demonstrated uptake of HK2 EVs by HK2 cells (Figure 1F), 
HK2 EVs by HCD cells (Figure 1G), and HCD EVs by HCD 
cells (Figure 1H) under our experimental conditions. No flu-
orescent signal was observed in cells exposed to a similarly 
processed mix of PKH67 and 5% (w/v) BSA without EVs 
(Supporting Information 2).
3.2 | HK2 and HCD EVs modulate 
extracellular ATP levels in HCD cells
The addition of HK2 EVs to HK2 cells (Figure  2A) did 
not significantly modify extracellular ATP levels after 
15  minutes of incubation. Similarly, the addition of nei-
ther HK2 (Figure 2B) nor HCD (Figure 2C) EVs to HCD 
cells for 15  minutes altered extracellular levels of ATP 
levels. Exposure of HK2 cells to HK2 EVs also did not 
F I G U R E  1  Characterization of EV suspensions from HK2 and HCD culture medium. EV suspensions were prepared by pooling six different 
EV preparations obtained by ultracentrifugation of HK2 and HCD culture medium. EVs were characterized by nanoparticle- tracking analysis (A 
and B), Western blotting for the EV marker CD63 (C) and transmission electron microscopy (D and E). Uptake of EVs by target cells was studied 
by exposure of target cells to PKH67- labeled EVs followed by fluorescence microscopy. HK2 EVs were added to HK2 cells (F), HK2 EVs were 
added to HCD cells (G) and HCD EVs were added to HCD cells (H). Scale bar in D and E: 200 nm. Scale bar in F- H: 100 μm
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F I G U R E  2  HK2 and HCD EVs regulate extracellular ATP levels in HCD cells. Extracellular ATP was studied in HK2 cells exposed to HK2 
EVs for 15 min (A) and 6 hours (D), in HCD cells exposed to HK2 EVs for 15 min (B) and 6 hours (E) and in HCD cells exposed to HCD EVs 
for 15 min (C) and 6 hours (F). The final concentration of EVs in the culture medium was 7x107 EVs /mL culture medium. Results (mean ± SEM) 
are expressed as fold- change of the extracellular ATP levels respect to cells not exposed to EVs (- EVs). *Different from - EVs, P < .05, n = 4 
(independent experiments). Dependence of the EV effects on the uptake by the target cells was determined using dynasore (80 μM) as an inhibitor 
of the EV uptake, or DMSO (control cells) in HK2 (G) and HCD cells (H). Results (mean ± SEM) are expressed as fold- change of the extracellular 
ATP levels respect to control cells not exposed to EVs (- EVs). a: different from control - EVs, b: different from control + EVs, c: different from 
dynasore - EVs. P < .05, n = 4 (independent experiments)
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significantly affect extracellular ATP levels at 6 hours of 
incubation (Figure 2D). However, at the latter time point, 
HCD cells exhibited a significant increase in extracellular 
ATP levels after exposure to similar HK2 EV suspensions 
(Figure 2E). Intra- EV ATP content for HK2 EVs was below 
the limit of detection, thus indicating that the previous ef-
fects cannot be attributed to the release of ATP from the 
EV lumen into the extracellular space of the target cells 
(data not shown). Exposure of HCD cells to HCD EVs 
led to a significant decrease in extracellular ATP levels 
(Figure 2F). These findings indicate a different response of 
collecting duct cells depending on the segment of origin of 
the vesicles. Treatment of HCD cells with suspensions from 
HK2 and HCD EVs subject to EV depletion did not modify 
extracellular ATP levels (Supporting Information 4A,B).
Incubation of HCD cells with HK2 EVs in the presence 
of dynasore prevented the effects of the EVs on extracellular 
ATP respect to the situation without dynasore (Figure 2G), 
suggesting an uptake- dependent mechanism. On the contrary, 
co- incubation with dynasore did not prevent the decrease in 
extracellular ATP in HCD cells exposed to HCD EVs, indi-
cating an uptake- independent effect (Figure 2H).
3.3 | Molecular mechanism of extracellular 
ATP upregulation by HK2 EVs
In order to gain further insight into the possible causes and 
consequences of extracellular ATP upregulation by HK2 
EVs in HCD cells, the mRNA expression of PANX1 (ie, 
ATP secreting channel), ectonucleotidases and purinergic 
receptors was studied. Addition of HK2 EVs to HCD cells 
led to a significant downregulation of ENTPD1 expres-
sion (Figure 3A). No significant changes were observed in 
the mRNA levels PANX1 or purinergic receptors P2RY1, 
P2RY2, and P2RY11 (Figure  3A). ENTPD1 protein ex-
pression was significantly downregulated in HCD cells 
treated with HK2 EVs (Figure 3B). In order to assess if the 
downregulation of ENTPD1 by HK2 EVs could explain the 
higher extracellular ATP levels, POM1 was used to inhibit 
ENTPD1 activity during incubation with EVs. Addition 
of POM1 prevented the increase in extracellular ATP by 
HK2 EVs (Figure 3C), suggesting that downregulation of 
ENTPD1 may indeed be responsible for increased extra-
cellular ATP levels in HCD cells. Nine miRNAs with the 
potential to regulate ENTPD1 in our experimental mod-
els were selected based on in silico analysis and literature 
evidence (Supporting Information 3). Among them, miR- 
205- 3p and miR- 505- 3p (Figure  3D) were significantly 
upregulated in HCD cells exposed to HK2 EVs, probably 
explaining the decreased expression of their target mRNA 
ENTPD1. All other candidate miRNAs studied were not 
significantly affected by exposure to EVs (Figure 3D).
3.4 | Molecular mechanism of extracellular 
ATP downregulation by HCD EVs
The addition of HCD EVs to HCD cells resulted in the down-
regulation of PANX1 (Figure 4A) mRNA expression, while 
no changes were observed in ENTPD1 or purinergic recep-
tors P2RY1, P2RY2, and P2RY11 (Figure 4A). PANX1 pro-
tein expression in HCD cells was not affected by HCD EVs 
(Supporting Information 4D). ENTPD2 expression in HCD 
cells was below the limit of detection (data not shown).
Since an uptake- independent mechanism was demon-
strated (Figure  2H), we determined the intrinsic ATPase 
activity of the EVs. Incubation of EVs in a noncellular sys-
tem supplemented with ATP showed ATPase activity for 
HCD vesicles after 6 hours of incubation (Figure 4B), while 
no changes were observed for HK2 vesicles (Supporting 
Information 4E). These observations may explain the uptake- 
independent decrease of extracellular ATP, once HCD EVs 
are added to HCD cells. Moreover, HCD EVs decreased ex-
tracellular ATP levels in HK2 cells (Supporting Information 
4F). Although this experimental condition may not resemble 
the direction of pro- urine and, therefore, EV flow along the 
nephron, the results support an effect of HCD EVs mainly de-
termined by ATPase activity due to the cargo of the vesicles 
and not by the nature of the target cell.
The protein cargo of EVs isolated from HK2 and HCD 
cells was analyzed using mass spectrometry (raw data avail-
able upon request). The results showed that 34 proteins were 
exclusively expressed in HK2 EVs, 137 in HCD EVs, and 26 
proteins were common for both types of vesicles (Figure 4C). 
From all the proteins identified, only the protein 14- 3- 3 has 
been previously reported to exhibit ATPase activity.53 A heat 
map was generated using label- free quantification (LFQ) in-
tensities to illustrate the higher abundance of 14- 3- 3 subunits 
in HCD EVs compared to HK2 vesicles. 14- 3- 3 βα, ε, γ, θ 
and ζδ were identified in HCD EVs, while only 14- 3- 3 ζδ 
was detected in HK2 EVs (Figure 4D).
3.5 | Effect of EVs on αENaC expression in 
HCD cells
ENaC is a well- known sodium channel mainly located in 
renal epithelia and associated to purinergic regulation.54 We 
observed a significant downregulation of SCNN1A (ie, gene 
codifying subunit α of ENaC) after exposure of HCD cells 
to HK2 EVs (Figure 5A). On the contrary, exposure of HCD 
cells to HCD EVs resulted in a significant SCNN1A upregula-
tion (Figure 5B). Incubation of HCD cells with apyrase (ie, 
total removal of extracellular ATP) significantly increased 
the SCNN1A expression. Furthermore, apyrase prevented 
the effects of HK2 and HCD EVs on SCNN1A expression 
in HCD cells (Figure 5C). Treatment with γ- S- ATP resulted 
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in a significant downregulation of SCNN1A (Figure  5D). 
Prevention of the effects of EVs by the P2YR inhibitor 
suramin indicates involvement of purinergic signaling in 
SCNN1A regulation by the vesicles (Figure 5E). These ob-
servations strongly suggest an inverse association between 
extracellular ATP levels and SCNN1A expression in our ex-
perimental model, whereby this relation can be modulated 
by the addition of EVs. To gain further insight into the mo-
lecular mechanisms leading to SCNN1A regulation upon ex-
posure of HCD cells to EVs and the consequent alteration 
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in extracellular ATP levels, intracellular cAMP levels were 
measured. In fact, HK2 EVs increased intracellular cAMP 
levels in HCD cells (Figure 6A). On the contrary, HCD EVs 
decreased intracellular cAMP levels (Figure 6B), again high-
lighting the opposite regulatory effect of proximal tubule and 
collecting duct EVs.
F I G U R E  3  Molecular mechanism underlying the upregulation of extracellular ATP by HK2 EVs in HCD cells. HCD cells were treated with 
HK2 EVs (7x107 EVs /mL culture medium, 6 hours). The expression of PANX1, ENTPD1, P2RY1, P2RY2, and P2RY11 was studied at the mRNA 
level by RT- qPCR. Results (mean ± SEM) for each gene are expressed as fold- change of the mRNA expression levels respect to cells not exposed 
to EVs (- EVs). RPS11 was used as housekeeping gene. *Different from - EVs, P < .05, n = 4 (independent experiments) (A). Protein expression of 
ENTPD1 was investigated by western blotting. β- Actin was used as a loading control. Results (mean ± SEM) are expressed as fold- change of the 
protein expression in cells not exposed to EVs (- EVs). *Different from - EVs, P < .05, n = 4 (independent experiments). Representative blots are 
shown at the bottom of the panel (B). To evaluate the participation of ENTPD1, HCD cells were treated with HK2 EVs (7x107 EVs /mL culture 
medium, 6 hours) in the presence or absence of POM1 (ENTPD1 inhibitor, 25 μM), added 30 minutes before addition of EVs. Extracellular ATP 
levels were determined by chemiluminescence (C). Results (mean ± SEM) are expressed as fold- change of the extracellular ATP levels respect 
to control cells not exposed to EVs or inhibitor (Control - EVs). a: Different from control – EVs, b: different from control + EVs, P < .05, n = 4 
(independent experiments). Expression analysis was performed for miR- 21, miR- 30a- 5p, miR- 30b- 5p, miR- 125b, miR- 205- 5p, miR- 205- 3p, miR- 
301a- 5p, miR- 505- 3p, and miR- 599. miRNA expression was normalized to the expression of the U6 snRNA (D). * Different from - EVs, P < .05, 
n = 3 (independent experiments)
F I G U R E  4  Molecular mechanism underlying the downregulation of extracellular ATP by HCD EVs in HCD cells. A, HCD cells were treated 
with HCD2 EVs (7x107 EVs /mL culture medium, 6 hours). The expression of PANX1, ENTPD1, P2RY1, P2RY2, and P2RY11 was studied at the 
mRNA level by RT- qPCR. Results (mean ± SEM) for each gene are expressed as fold- change of the mRNA expression levels respect to cells not 
exposed to EVs (- EVs). RPS11 was used as housekeeping gene. *Different from - EVs, P < .05, n = 3- 4 (independent experiments). B, To evaluate 
the intrinsic ATPase activity, HCD EVs were added to a reaction medium containing ATP and incubated for 4 h at 37°C. Then, the remaining ATP 
concentration was determined by chemiluminescence. Results (mean ± SEM) are expressed as fold- change of the ATP concentration in a reaction 
medium without addition of EVs (- EVs). *Different from - EVs, P < .05, n = 3 (independent experiments). C, Number of proteins identified by 
mass spectrometry only in HK2 EVs (left), in HK2 and HCD EVs (center) and only in HCD EVs (right). D, Heat map showing differences in the 
expression levels (Log2 LFQ Intensity) of the different subunits of the 14- 3- 3 protein in HK2 and HCD EVs. Subunits indicated in bold have been 
described to exhibit ATPase activity
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3.6 | Aldosterone modulates the release and 
activity of EVs on HCD cells
We demonstrated an inverse association between extracellu-
lar ATP levels and αENaC mRNA expression upon the ex-
posure to EVs (Figure 5). Aldosterone is known to modulate 
extracellular ATP levels and αENaC functionality.2 To inves-
tigate whether aldosterone can contribute to the regulation of 
purinergic signaling by EVs, as observed in this study, the ef-
fect of aldosterone on EV release and on the ability of EVs to 
modify extracellular ATP was determined in HK2 and HCD 
cells. No significant changes were observed in the EV release 
by aldosterone- treated HK2 cells with respect to control cells 
(Figure  7A). However, aldosterone significantly increased 
EV release in HCD cells compared to the control conditions 
(Figure  7B). Furthermore, EV suspensions obtained from 
aldosterone- treated HCD cells led significantly to lower ex-
tracellular ATP levels in HCD cells compared to EVs iso-
lated from control HCD cells (Figure 7D). On the contrary, 
no significant effects on extracellular ATP levels were ob-
served when EVs from control and aldosterone- conditioned 
HK2 cells were added to HCD cells (Figure 7C). Moreover, 
incubation of HCD cells with uEVs from PA patients also 
decreased extracellular ATP (Figure  7E) and upregulated 
F I G U R E  5  Regulation of SCNN1A mRNA expression by EVs and extracellular ATP levels in HCD cells. Expression of SCNN1A (gene 
codifying αENaC) was determined in HCD cells exposed to HK2 (A) and HCD EVs (B) (7x107 EVs /mL culture medium, 6 hours) by RT- qPCR 
with RPS11 as a housekeeping gene. Results (mean ± SEM) are expressed as fold- change of SCNN1A expression in cells not exposed to EVs 
(- EVs). *Different from - EVs, P < .05, n = 4 (independent experiments). C, Dependence of the effects by EVs (7x107 EVs /mL culture medium, 
6 hours) on the alteration of extracellular ATP levels was assessed by coincubation with apyrase (24 U mL- 1). Results (mean ± SEM) are expressed 
as fold- change of SCNN1A expression in control cells not exposed to EVs (Control - EVs), n = 3 (independent experiments). D, Effect of γ- S- 
ATP (5 and 50 μM, 6 hours) on SCNN1A expression in HCD cells. Results (mean ± SEM) are expressed as fold- change of SCNN1A expression 
in control cells. *Different from control, P < .05, n = 4 (independent experiments). E, Dependence of the effects by EVs (7x107 EVs /mL culture 
medium, 6 hours) on purinergic signaling was assessed by coincubation with suramin (50 μM). Results (mean ± SEM) are expressed as fold- 
change of SCNN1A expression respect to control cells not exposed to EVs (Control - EVs), n = 4 (independent experiments)
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αENaC (Figure 7F) with respect to cells incubated with uEVs 
from healthy donors. These findings highlight the influence 
of aldosterone on the regulation of purinergic signaling and 
αENaC by EVs.
4 |  DISCUSSION
Purinergic signaling constitutes a major regulatory mecha-
nism involved in renal function.1,3 Moreover, EVs from ex-
trarenal tissues have shown to act as purinergic signaling 
regulators by modulating extracellular ATP levels.22,55 Our 
current study constitutes the first report describing the modu-
lation of renal purinergic signaling by EVs. Moreover, our 
data, showing regulation of purinergic signaling in collect-
ing duct cells by proximal tubule EVs, indicates the potential 
of EVs to mediate intersegment communication along the 
nephron.
Extracellular ATP in HCD cells increased with long- term 
exposure to HK2 EVs (Figure 2E). Furthermore, the preven-
tion of this effect by dynasore (Figure 2G) suggests a mecha-
nism dependent on the endocytosis of the EVs by HCD cells, 
as dynasore inhibits dynamin 2, a key component of clathrin- 
mediated endocytosis and caveolin- dependent endocytosis.56 
Concomitant downregulation of ENTPD1 could explain de-
creased hydrolysis and, therefore, higher extracellular ATP 
levels. Effects on extracellular ATP were only observed after 
6  hours of incubation, without changes after a short- term 
incubation. In this regard, the regulation of ENTPD1 at the 
mRNA and protein level may account for the longer incuba-
tion time required for the effects to take place. An increase in 
extracellular ATP upon ENTPD1 downregulation has been 
described in extra- renal models, where extracellular ATP lev-
els modulated by CD39 regulate P2Y2R- mediated puriner-
gic signaling.57 Additionally, cancer- derived exosomes were 
described to regulate CD73, another ectonucleotidase, when 
added to dendritic cells.58 Our results constitute the first study 
describing the modulation of ENTPD1 by EVs in the kidney.
MiRNAs are known negative regulators of mRNA expres-
sion. Additionally, miRNAs transfer via EVs is a common 
mechanism of cell- cell communication, also in the kidney.20 
In the current work, we observed an upregulation of miR- 
205- 3p and miR- 505- 3p in HCD cells exposed to HK2 EVs 
(Figure  3C). Our data are in line with previous studies re-
porting the presence of both miRNAs in HK2 cells.59- 61 
Furthermore, miR- 205 was also described in human UEVs.20 
Since both miRNAs target ENTPD1 mRNA, their upregu-
lation may explain ENTPD1 downregulation, whereby the 
transfer of the miRNAs from HK2 to HCD cells via EVs ap-
pears as a likely mechanism. This, however, would need to be 
ultimately confirmed by using inhibitors against these par-
ticular miRNAs. Considering the role of extracellular ATP 
in renal physiology and in the development of pathologies 
such as renal injury, polycystic kidney disease and diabetic 
nephropathy,54 this could potentially yield novel therapeutic 
targets to be explored.
Contrarily to the effects upon addition of HK2 EVs, incu-
bation of HCD cells with HCD EVs decreased extracellular 
ATP levels (Figure 2F), being this effect not prevented by the 
co- incubation with dynasore (Figure 2H). Although dynamin 
2- independent uptake mechanisms have been described and 
cannot be fully ruled out, processes dependent on clathrin and 
caveolin, which are inhibited by dynasore, constitute the most 
frequent internalization mechanisms for EVs.56 Therefore, 
our results support an uptake- independent process in HCD 
EVs- mediated effects. In principle, a decrease in PANX1 ex-
pression by EVs (Figure 4A) may have also contributed to 
explaining the decrease in extracellular ATP upon addition 
of HCD EVs to HCD cells. However, the downregulation 
was not reproduced at the protein level (supporting informa-
tion 4D), indicating a minor role of ATP secretion in the dif-
ferences observed after incubation with EVs. Furthermore, 
positive feedback regulation of PANX1 by extracellular ATP 
has been described.62 In that sense, the downregulation of 
PANX1 mRNA after the addition of EVs could be a con-
sequence of reduced extracellular ATP levels rather than a 
F I G U R E  6  Effect of HK2 and HCD 
EVs on intracellular cAMP levels in HCD 
cells. Intracellular cAMP was studied in 
HCD cells treated with HK2 EVs (7x107 
EVs/mL culture medium, 6 hours) (A) and 
HCD EVs (7x107 EVs/mL culture medium, 
6 hours) (B). Results (mean ± SEM) 
are expressed as fold- change of values 
respect to cells not exposed to EVs (- EVs). 
*Different from - EVs, P < .05, n = 4 
(independent experiments)
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cause. Also, our data demonstrates an ATP- hydrolyzing ac-
tivity by HCD EVs (Figure 4B), unlike HK2 EVs, which is 
in line with previous evidence for cancer- derived,22 and sa-
liva exosomes.55 Proteomics analysis of HK2 and HCD EVs 
clearly exhibited an enrichment in different subunits of the 
protein 14- 3- 3 in HCD vesicles. Noteworthy, subunits γ, ε, 
and ζ have demonstrated ATPase activity.53 Altogether, these 
findings support an uptake- independent mechanism, where 
HCD EVs hydrolyze extracellular ATP in HCD cells due to 
intrinsic ATPase activity present in their cargo.
Inhibition of αENaC by extracellular ATP is a well- 
known process under physiological24 and pathophysiological 
F I G U R E  7  Effect of aldosterone 
on EV release and extracellular ATP. 
EV release was studied in control and 
aldosterone- treated (100 nM, 24 hours) 
HK2 (A) and HCD cells (B). The number 
of particles released to the cell supernatant 
was assessed by nanoparticle- tracking 
analysis. Results (mean ± SEM) are 
expressed as number of particles released 
per mL of culture medium. *Different from 
control cells, P < .05, n = 4 (independent 
experiments). The differential effect of 
HK2 (C) and HCD EVs (D) from control 
cells and aldosterone- treated cells (100 nM, 
24 hours) on extracellular ATP levels was 
assessed in HCD cells. Cells were exposed 
to equal volumes (0.02 μL EV suspension 
per μL culture medium, 6 hours) and 
extracellular ATP levels were assessed 
by chemiluminescence. Results for each 
independent experiment are expressed 
as the fold- change of extracellular ATP 
levels in cells exposed to EVs from control 
cells, *different from control, P < .05, 
n = 4 (independent experiments). The 
effect of uEVs from healthy donors and 
PA patients on extracellular ATP (E) and 
SCNN1A expression (F) was quantified 
by chemiluminescence and RT- qPCR, 
respectively. * Different from healthy uEVs, 
P < .05. n = 4- 5 (independent experiments)
   | 15 of 18BARROS LAMUS et AL.
conditions.63 Previously reported evidence points to a short- 
term regulation at the channel activity level upon the increase 
in extracellular ATP levels and activation of purinergic recep-
tors.64 Our findings, reveal an inverse association between 
extracellular ATP and αENaC mRNA expression after the 
addition of HK2 and HCD EVs (Figure  5), suggesting that 
this purinergic regulation also takes place at the gene expres-
sion level. The latter is in line with previous reports that have 
shown in collecting duct cells that ENaC activity decreases 
with increased extracellular ATP.65 Downregulation of αENaC 
expression by γ- S- ATP and upregulation by apyrase (ie, total 
removal of extracellular ATP) further supports this associa-
tion. Finally, prevention of the effects of the EVs by apyrase 
and suramin strongly supports a dependence on the modulation 
of extracellular ATP levels and activation of P2Y receptors, 
respectively. To gain a deeper insight into the underlying mo-
lecular mechanisms, we evaluated intracellular cAMP levels, 
as a second messenger frequently accompanying P2Y266 and 
P2Y1167 activation by ATP. Our results showed an increase 
in intracellular cAMP levels by HK2 EVs and a decrease by 
HCD EVs, in parallel with an increase and a decrease in extra-
cellular ATP levels, respectively. Interestingly, although previ-
ous reports demonstrated upregulation of αENaC expression 
by cAMP in rat submandibular gland epithelial cells68 and 
in rat kidney,69 downregulation of the channel expression by 
cAMP was, on the contrary, observed in rat lung70 and in en-
dothelial cells.71 Discrepancies may be attributed to different 
signaling pathways and molecules being activated in the var-
ious cases, of which cAMP could be only one of them, under 
the different stimuli applied (eg, hormones, direct exposure to 
cAMP analogues, etc). In the present work, we demonstrated 
a direct association between extracellular ATP and cAMP, 
and an inverse association between their levels and αENaC 
expression. Furthermore, the participation of P2Y receptors 
in the regulation of αENaC by EVs was shown, among which 
downstream signaling via cAMP is well- known.66,67 Although 
further studies should be performed to confirm and elucidate 
the mechanism inversely associating cAMP levels and αENaC 
mRNA levels, our findings suggest the participation of this 
second messenger in the downregulation of the channel ex-
pression by ATP and therefore, by EVs.
Previous evidence has demonstrated that the effects of 
aldosterone on ENaC activity and the consequent sodium re-
absorption can depend on the release of ATP.72 On the other 
hand, aldosterone has also been shown to increase the release 
of EVs from endothelial cells,73 while PA patients have also 
shown to have more circulating EVs than essential hyperten-
sives.74 The latter, along with our results (Figure 7), suggests 
that in renal cells, aldosterone effects on ATP and ENaC 
might be regulated, at least in part, by the release of EVs to 
the extracellular space.
Furthermore, sodium intake has been shown to activate 
ATP release by connexin 30 (Cx30) that in turn decreases 
ENaC activity in the distal part of the nephron.2 This also 
highlights an inverse association between extracellular ATP 
and ENaC, as displayed by our data, where ENaC expres-
sion was reduced in HCD cells upon the addition of HK2 
EVs. Overall, it seems plausible that proximal tubule EVs 
can contribute to this paracrine purinergic signaling in order 
to regulate the activity and expression of ENaC. Moreover, 
Cx30- /-  K.O mice (ie, lower extracellular ATP) show a hyper-
active ENaC,2 which agrees with our observations where al-
dosterone stimulates the release of EVs with ATP hydrolytic 
activity in HCD cells, ultimately downregulating ENaC ex-
pression. These results suggest a novel mechanism by which 
14- 3- 3 protein regulates ENaC, in addition to its known ef-
fects on the ubiquitin E3 ligase Nedd- 4- 2, which leads to an 
increase in ENaC abundance and activity.75,76 In agreement 
with this, uEVs from PA patients, which have higher serum 
aldosterone levels, activated ENaC and increased sodium re-
absorption, decreased extracellular ATP and up`regulated the 
in vitro expression of αENaC on HCD cells. In relation with 
this, a previous study reported the inhibition of EV release by 
the well- known ENaC inhibitor amiloride.77 Altogether, this 
points toward the fact that EVs contribute to different mech-
anisms that regulate extracellular levels of ATP and ENaC 
activation, encouraging further studies at this level.
The enclosed nature of EVs, defined by a lipidic bilayer, 
allows the shuttle of information (determined by the EV 
cargo) between cells, protected from external factors that 
may result in an attenuation or significant modification of 
the message. Previous reports already described the transfer 
of information between proximal tubule (donor cells) to dis-
tal tubule and collecting duct cells (target cells) via EVs.17,78 
This mechanism allows the donor cell to sense different con-
ditions in its intra- and extracellular environment and transmit 
an according message to other cells. In the case of purinergic 
signaling along the nephron, when signaling nucleotides are 
released to the pro- urine, they can be hydrolyzed by several 
ectoATPases expressed along the tubules, 79,80 resulting in a 
modification of the signaling information before it reaches 
the purinergic receptors in downstream segments. In this 
sense, remote regulation via EVs could be an efficient com-
munication mechanism for the transfer of information from 
proximal to collecting duct cells.
Although our findings provide relevant evidence on the 
role of EV- mediated signaling between renal epithelial cells, 
our study bears some limitations, partially inherent to the 
state- of- the- art in EV research, which should be taken into 
consideration. For instance, due to the lack of reports on 
the intratubular concentration of EVs, it is difficult to esti-
mate whether the concentration of vesicles used in our stud-
ies mimic the situation in vivo. Noteworthy, we defined the 
concentrations of EVs based parameters previously used in 
other studies such as concentration of particles20 and con-
centration of proteins.74 In addition, our data point to a clear 
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transcriptional regulation of αENaC by EVs. Further studies 
should be performed to confirm the impact of these changes 
at the protein and activity level.
In summary, we demonstrated the regulation of puriner-
gic signaling and αENaC mRNA expression by EVs between 
proximal tubule and collecting duct cells in vitro as well as 
within the collecting duct, being the latter sensitive to aldo-
sterone. These findings confirm the regulation of renal puri-
nergic signaling by EVs, as previously demonstrated in other 
tissues. Furthermore, our work points to a new role for EVs in 
intercellular communication in the kidney that may not only 
affect sodium balance, but also other physiological and patho-
physiological processes affected by purinergic signaling.
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